U.S., EUROPE, AND CHINA MYELODYSPLASTIC SYNDROME (MDS) TREATMENT MARKE ANALYSIS

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, by Drugs (Lenalidomide, Decitabine, Azacitidine, Luspatercept, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country/Region (U.S., Europe, and China) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Jul 2021
Code : CMI4513
Pages :255
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key Players

Major players operating in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.

Companies covered:

Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.